A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer
An Multi-center, Open-label Phase Ib/II Study of Gentuximab Injection + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer to Evaluate Tolerability, Safety, Efficacy and Pharmacokinetics.
Studieöversikt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljerad beskrivning
Studietyp
Studietyp
Inskrivning (Faktisk)
Inskrivning
Fas
Fas
- Fas 2
- Fas 1
Kontakter och platser
Studiekontakt
Studiekontakt
- Namn: Siqin Wang
- E-post: wangsiqin@gensci-china.com
Studera Kontakt Backup
- Namn: Jin Li
- Telefonnummer: 13761222111
- E-post: tianyoulijin@163.com
Studieorter
-
-
-
Shanghai, Kina
- Shanghai First People's Hospital
-
Shanghai, Kina
- Shanghai East Hospital
-
-
Fujian
-
Fuzhou, Fujian, Kina
- Fujian Tumor Hospital
-
-
Guangdong
-
Guangzhou, Guangdong, Kina
- The Sixth Hospital of Sun Yat-sen University
-
-
Heilongjiang
-
Harbin, Heilongjiang, Kina
- The Affiliated Tumor Hospital of Harbin Medical University
-
-
Henan
-
Zhengzhou, Henan, Kina
- The First Affiliated Hospital of Zhengzhou University
-
-
Hubei
-
Wuhan, Hubei, Kina
- Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
-
-
Jiangsu
-
Nanjing, Jiangsu, Kina
- Jiangsu Province Hospital
-
-
Jilin
-
Changchun, Jilin, Kina
- The First Hospital of Jilin University
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kina
- The First Affiliated Hospital, Zhejiang University School of Medicine
-
Hangzhou, Zhejiang, Kina
- Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
-
Hangzhou, Zhejiang, Kina
- Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
-
-
Deltagandekriterier
Urvalskriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- The subject can understand the process and methods of the study, complete the study in accordance with the protocol and is willing to sign a written informed consent.
- Male or female. aged between 18 and 75 years
- Histopathologically confirmed advanced advanced gastric or gastroesophageal junction cancer, and Documented progression during first-line fluoropyrimidine- and platinum- containing chemotherapy, or during the 3 months following the last cycle of such chemotherapy (or during the 6 months following the last dose of adjuvant therapy or new adjuvant therapy containing fluoropyrimidine and platinium).
- At least one Measurable lesion.
- ECOG Performance status (PS) score, 0-1 level.
- A life expectancy of >3 months.
- Adequate hematologic function, as defined by: Absolute neutrophil count (ANC) ≥1.5×109/L; hemoglobin concentration ≥90g/L (allowing blood transfusion); and platelet count ≥80×109/L.
- Adequate hepatic function, as defined by: ALT ≤ 2.5 × ULN, AST ≤ 2.5 × ULN, TBIL ≤ 1.5 × ULN (liver metastases patients ALT ≤ 5 × ULN, AST ≤ 5 × ULN, TBIL ≤ 3 × ULN).
- Adequate renal function, as defined by: serum creatinine level≤ 1.5 × ULN, or creatinine clearance ≥ 50ml / min when serum creatinine level> 1.5 × ULN.
- Adequate coagulation function, as defined by: International normalized ratio (INR) ≤1.5× ULN, activated partial thromboplastin time (aPTT) ≤1.5 x ULN.
- 24-hour urine protein quantitation is <1g(24-hour urine protein quantitative test should be performed when urine protein ≥1+ is found during screening visit).
- Subjects (male and female) who have fertility must agree to use reliable contraceptive methods during the trial and in 3 months after the last administration. Female subjects in childbearing age must be negative for blood pregnancy test prior to enrollment.
Exclusion Criteria:
- Previously administrated with anti-angiogenic drugs or paclitaxel.
- Systematic anti-tumor therapy (non-anti-angiogenic drugs or paclitaxel) such as chemotherapy, radiotherapy, macromolecular targeted therapy, immunotherapy, endocrine therapy, etc. within 4 weeks before the first dose of investigational drug, except for the following: nitrourea or mitomycin C is within 6 weeks before the first dose, oral fluorouracil and small molecule targeted drugs are within 2 weeks or 5 half-life of the drug(whichever is longer) before the first dose,Chinese medicine with anti-cancer indications is within 2 weeks before the first dose.
- Has participated in a clinical study of a non-approved experimental agent within 4 weeks prior to screening visit.
- Has undergone major surgery within 4 weeks before screening visit (not including needle biopsy), or would undergo planned surgery during the study.
- Subject with positive HCV-Ab, Anti-HIV or TP-Ab, or positive HBS-Ag with copies of HBV DNA > ULN.
- Patients with previously confirmed malignant tumors.
- History of arterial thrombosis or deep vein thrombosis within 6 months prior to screening, or a bleeding event no less than Grade level 3 within 2 months prior to screening, or the investigator determines that there is a risk of bleeding.
- History of severe cardiovascular and cerebrovascular diseases.
- Subjects with confirmed brain tumor metastases,but subjects in steady situation can be enrolled.
- Active bleeding confirmed by gastroscopy when fecal occult blood positive (only subjects with primary lesions not removed need to do fecal occult blood test.
- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 12 months before screening visit.
- Thoracic,abdominal or pericardial effusion that cannot be controlled by repeated drainage or with obvious symptoms.
- Has a nonhealing wound, serious ulcer, or unrecovered bone fracture.
- Active infections requiring systemic treatment, including but not limited to active tuberculosis.
- Using anticoagulation and antiplatelet drugs.
- Female subjects who is pregnant (confirmed by urine or serum pregnancy test) or lactating.
- Has a known serious allergy reaction to recombination monoclonal antibody (MAb) drug, ,or infusion reaction.
- Has known alcohol or drug dependency.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Antal vapen
Vapen och interventioner
Deltagargrupp / ArmDeltagargrupp / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Experimentell: 1 Gentuximab+ Paclitaxel
8 mg/kg Gentuximab administered intravenously (IV) on D1 and D15(28 days every cycle)+ 80 mg/m² paclitaxel administered IV on D1, D8 and D15
|
Administered intravenously (IV)
Administrerat intravenöst (iv)
|
|
Experimentell: 2 Gentuximab+ Paclitaxel
12 mg/kg Gentuximab administered intravenously (IV) on D1 and D15(28 days every cycle)+ 80 mg/m² paclitaxel administered IV on D1, D8 and D15
|
Administered intravenously (IV)
Administrerat intravenöst (iv)
|
Vad mäter studien?
Primära resultatmått
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Dose-limiting toxicities (DLT)
Tidsram: Up to 4 Weeks
|
Number of Participants With One or More Drug-Related Adverse Events (AEs) defined as DLT in the protocol
|
Up to 4 Weeks
|
|
AEs or SAEs
Tidsram: Baseline through Study Completion, about 24 weeks
|
Drug-Related Adverse Events (AEs) or Any Serious Adverse Events (SAEs)
|
Baseline through Study Completion, about 24 weeks
|
Sekundära resultatmått
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Objective response rate(ORR)
Tidsram: Up to 6 cycles (28 days for every cycle)
|
Proportion of Participants With CR and PR
|
Up to 6 cycles (28 days for every cycle)
|
|
Progression-free survival (PFS)
Tidsram: Up to 6 cycles (28 days for every cycle)
|
The time from randomization to the patient tumor progression or death.
|
Up to 6 cycles (28 days for every cycle)
|
|
Disease control rate (DCR)
Tidsram: Up to 6 cycles (28 days for every cycle)
|
Proportion of Participants With CR, PR and SD
|
Up to 6 cycles (28 days for every cycle)
|
|
Time-to-progress (TTP)
Tidsram: Up to 6 cycles (28 days for every cycle)
|
The time from randomization to the patient tumor progression.
|
Up to 6 cycles (28 days for every cycle)
|
|
Time-to-failure (TTF)
Tidsram: Up to 6 cycles (28 days for every cycle)
|
The time from randomization to the patient withdraw from the study.
|
Up to 6 cycles (28 days for every cycle)
|
|
Anti-drug antibody
Tidsram: Up to 6 cycles (28 days for every cycle)
|
Number of Participants With Anti-drug Antibodies
|
Up to 6 cycles (28 days for every cycle)
|
|
Pharmacokinetics Cmax
Tidsram: Cycle 1(day1-day 15)& Cycle 2(day 15-day26) & Cycle 3(day 1) (28 days for every cycle)
|
Maximum Concentration (Cmax)
|
Cycle 1(day1-day 15)& Cycle 2(day 15-day26) & Cycle 3(day 1) (28 days for every cycle)
|
|
Area Under the Concentration-Time Curve (AUC)
Tidsram: Cycle 1(day1-day 15)& Cycle 2(day 15-day26) & Cycle 3(day 1) Cycle 1(day1-day 15)& Cycle 2(day 15-day26) & Cycle 3(day 1) (28 days for every cycle)
|
Cycle 1(day1-day 15)& Cycle 2(day 15-day26) & Cycle 3(day 1) Cycle 1(day1-day 15)& Cycle 2(day 15-day26) & Cycle 3(day 1) (28 days for every cycle)
|
Samarbetspartners och utredare
Sponsor
Sponsor
Samarbetspartners
Samarbetspartners
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Studiestart
Primärt slutförande (Faktisk)
Primärt slutförande
Avslutad studie (Faktisk)
Avslutad studie
Studieregistreringsdatum
Först inskickad
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Första postat
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste uppdatering publicerad
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
Andra studie-ID-nummer
- GenSci 043 CT
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .